These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
379 related articles for article (PubMed ID: 35327542)
1. Insights into Human-Induced Pluripotent Stem Cell-Derived Astrocytes in Neurodegenerative Disorders. Kumar M; Nguyen NTP; Milanese M; Bonanno G Biomolecules; 2022 Feb; 12(3):. PubMed ID: 35327542 [TBL] [Abstract][Full Text] [Related]
2. Human Astrocytes Model Derived from Induced Pluripotent Stem Cells. Leventoux N; Morimoto S; Imaizumi K; Sato Y; Takahashi S; Mashima K; Ishikawa M; Sonn I; Kondo T; Watanabe H; Okano H Cells; 2020 Dec; 9(12):. PubMed ID: 33322219 [TBL] [Abstract][Full Text] [Related]
3. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology. Liu Y; Deng W Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934 [TBL] [Abstract][Full Text] [Related]
4. Astrocyte alterations in neurodegenerative pathologies and their modeling in human induced pluripotent stem cell platforms. Oksanen M; Lehtonen S; Jaronen M; Goldsteins G; Hämäläinen RH; Koistinaho J Cell Mol Life Sci; 2019 Jul; 76(14):2739-2760. PubMed ID: 31016348 [TBL] [Abstract][Full Text] [Related]
5. Differentiation of Inflammation-Responsive Astrocytes from Glial Progenitors Generated from Human Induced Pluripotent Stem Cells. Santos R; Vadodaria KC; Jaeger BN; Mei A; Lefcochilos-Fogelquist S; Mendes APD; Erikson G; Shokhirev M; Randolph-Moore L; Fredlender C; Dave S; Oefner R; Fitzpatrick C; Pena M; Barron JJ; Ku M; Denli AM; Kerman BE; Charnay P; Kelsoe JR; Marchetto MC; Gage FH Stem Cell Reports; 2017 Jun; 8(6):1757-1769. PubMed ID: 28591655 [TBL] [Abstract][Full Text] [Related]
6. Modeling Neurological Disorders with Human Pluripotent Stem Cell-Derived Astrocytes. Suga M; Kondo T; Inoue H Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31398826 [TBL] [Abstract][Full Text] [Related]
7. Metabolic and immune dysfunction of glia in neurodegenerative disorders: Focus on iPSC models. Rõlova T; Lehtonen Š; Goldsteins G; Kettunen P; Koistinaho J Stem Cells; 2021 Mar; 39(3):256-265. PubMed ID: 33270954 [TBL] [Abstract][Full Text] [Related]
8. Reprogramming of HUVECs into induced pluripotent stem cells (HiPSCs), generation and characterization of HiPSC-derived neurons and astrocytes. Haile Y; Nakhaei-Nejad M; Boakye PA; Baker G; Smith PA; Murray AG; Giuliani F; Jahroudi N PLoS One; 2015; 10(3):e0119617. PubMed ID: 25789622 [TBL] [Abstract][Full Text] [Related]
9. Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening. Chang CY; Ting HC; Liu CA; Su HL; Chiou TW; Lin SZ; Harn HJ; Ho TJ Molecules; 2020 Apr; 25(8):. PubMed ID: 32344649 [TBL] [Abstract][Full Text] [Related]
10. Astrocytes generated from patient induced pluripotent stem cells recapitulate features of Huntington's disease patient cells. Juopperi TA; Kim WR; Chiang CH; Yu H; Margolis RL; Ross CA; Ming GL; Song H Mol Brain; 2012 May; 5():17. PubMed ID: 22613578 [TBL] [Abstract][Full Text] [Related]
11. Improved modeling of human AD with an automated culturing platform for iPSC neurons, astrocytes and microglia. Bassil R; Shields K; Granger K; Zein I; Ng S; Chih B Nat Commun; 2021 Sep; 12(1):5220. PubMed ID: 34471104 [TBL] [Abstract][Full Text] [Related]
12. Modeling and Targeting Neuroglial Interactions with Human Pluripotent Stem Cell Models. Bigarreau J; Rouach N; Perrier AL; Mouthon F; Charvériat M Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163606 [TBL] [Abstract][Full Text] [Related]